Ignite Creation Date:
2024-05-06 @ 5:58 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05494580
Status:
RECRUITING
Last Update Posted:
2023-04-11
First Post:
2022-07-26
Brief Title:
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly ADP-ribose Polymerase PARP Inhibitors a Multicenter Single-arm Phase IbII Trial
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A number of studies suggest that the combination of PARP inhibitors and antiangiogenic agents produce synergistic activities Pamiparib is a small molecule inhibitor selectivity for both PARP1 and PARP2 Surufatinib is a novel small-molecule inhibitor that simultaneously targets tumor angiogenesis via Vascular Endothelial Growth Factor Receptor VEGFR1 VEGFR 2 VEGFR3 and Fibroblast Growth Factor Receptor 1 FGFR1 and immune evasion via Colony Stimulating Factor 1 Receptor CSF1R In this trial we aimed to evaluate the efficacy safety and tolerability of pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior PARP inhibitors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None